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Although people living with HIV (PLHIV) are approaching normal life expectancy, a
limitation to achieving this goal is managing the higher prevalence of co-morbidities,
including cardiovascular disease. Whilst ischaemic heart disease likely contributes to a
large proportion of cardiac disease in the modern era of treatment, cardio-metabolic
disease, including cardiac steatosis, akin to obesity-related heart disease, is also
a possible mechanism of increased cardiac morbidity and mortality. HIV and other
metabolic and inflammatory diseases affecting the heart, including obesity, share
many cardio-metabolic abnormalities, with increased pericardial and myocardial fat
content, in association with chronic systemic inflammatory changes and alterations in
cardiac metabolism. Understanding the mechanisms of HIV-associated cardiac steatosis
remains an important challenge, as managing the untreated metabolic and inflammatory
precipitants may substantially improve cardiac outcomes for PLHIV.
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INTRODUCTION
Since the introduction of combined antiretroviral therapy (cART), HIV infection is recognized
as a chronic manageable systemic condition. Cardiovascular Disease (CVD) remains a leading
cause of death among PLHIV surviving more than 10 years after commencing cART (1). With the
introduction of highly effective antiretroviral therapies, all-cause mortality in PLHIV decreased,
however, CVD mortality has increased and is expected to continue to rise as cART availability
expands to low-income countries (2). The exact nature of cardiac disease in the modern era of
PLHIV has not been well established and this review considers the association of abnormal cardiac
fat metabolism and deposition as a potential contributor to the increased cardiac morbidity and
mortality seen in PLHIV.

CARDIAC DISEASE IN PLHIV
Poorly controlled HIV with the development of acquired immunodeficiency syndrome (AIDS) was
associated with the development of pericardial diseases and cardiomyopathy, both of which were
linked to reduced survival (3, 4). Heart failure in those with untreated HIV typically presented
with left ventricular dilation and systolic dysfunction, with a median survival of 101 days after
diagnosis (5). The incidence of HIV associated cardiomyopathy has significantly declined since the
introduction of cART (4) and a modern cohort of PLHIV are more likely to suffer from ischaemic
heart disease, myocarditis and the cardiac complications of systemic inflammatory and metabolic
derangement (6, 7). Whilst the incidence of heart failure in PLHIV has overall reduced, heart failure
remains more prevalent in PLHIV compared to negative controls. In a 2017 cohort study of 98,015,
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veterans living with HIV were at increased risk of heart failure
with preserved ejection fraction, borderline heart failure with
preserved ejection fraction and heart failure with reduced
ejection fraction, with hazard ratio of 1.21, 1.37, and 1.61,
respectively. Heart failure with preserved ejection fraction
accounts for the greatest proportion of cases (8). The mechanism
underlying the ongoing elevated incidence of heart failure in
PLHIV using highly effective ART remains unknown, though it
is likely multifactorial and partly related to abnormalities in fat
metabolism.
Whilst HIV has been associated with all forms of cardiac
disease, the focus has more recently shifted toward prevention
of ischaemic heart disease. Males on cART, by the age 60, have
a cumulative CVD incidence estimated at 20.5% compared to
14.6% in HIV-negative high-risk persons, and 12.8% in the US
general population (9). Hence, HIV remains an important CVD
risk factor in PLHIV using highly effective ART.

with age-matched control subjects. Participants living with HIV
undergoing cART (n = 90; 69.77%) had 47% higher median
myocardial lipid levels (P < 0.003, Figure 1) and 74% higher
median plasma triglyceride levels (both P < 0.001) (7). The
association between PLHIV on ART and myocardial fat remained
after adjustment for potential known confounders. The presence
of cardiac steatosis was associated with elevated serum lipid level
in subjects with HIV. However, positron emission tomography
has demonstrated no changes in myocardial fatty acid uptake,
esterification, and utilization in PLHIV compared with control
subjects (15). Whilst an important technique to provide insights
into disease, MRS is not yet a clinical tool and we do not advocate
the use of cardiac MR or PET scans for the routine assessment of
asymptomatic subjects with HIV.
HIV infection is linked to dysfunction in fat and glucose
metabolism independent of ART (16). However, ART has also
been shown to contribute to the metabolic dysfunction in
PLHIV. Early ART regimen, in particularly protease inhibitors,
are associated with visceral lipohypertrophy, dyslipidaemia and
insulin resistance (17). Comparative studies between older and
newer ART regimens have demonstrated improved metabolic
profile with the use of newer ART regimen (18). However, longterm exposure to antiretroviral medications remains a metabolic
risk for PLHIV. Among HIV-infected men, after adjustment
for age, race and cardiovascular risk factors, epicardial adipose
tissue volume was associated with the duration of combined
ART (12). ART regimen including darunavir and atazanavir,
which have been recommended by the Department of Health and
Human Services (DHHS) for their favorable impact on glucose
and lipid metabolism, have been associated with significant
gain in limb fat, subcutaneous fat, visceral fat and trunk fat
(19). Peripheral metabolic complications in other diseases, such
as diabetes mellitus and obesity, are associated with cardiac
functional derangements, morbidity, and mortality, which are
independent of blood pressure, body mass index, and coronary
disease. Whether lipid and glucose abnormalities predispose to
cardiac metabolic alterations and deposition of pericardial and
myocardial fat in PLHIV remains unknown.

CARDIAC STEATOSIS IN PLHIV
Abnormalities in cardiac fat metabolism have been described in
obese individuals, including increased epicardial and myocardial
fat (10). The presence of visceral adipose tissue (VAT) is the best
predictor of pericardial fat in non-diabetic abdominally obese
subjects (11). Increased pericardial fat content is not exclusive
to obese individuals and has been found in PLHIV. This was
demonstrated in a large cohort study of 579 men with HIV and
353 men without HIV aged 40–70 years old, where epicardial
adipose tissue (EAT) volume was assessed non-invasively via
computed tomography. Men with HIV were found to have
increased EAT compared to controls (p = 0.001), independent
of other measures of adiposity including visceral adipose tissue
and body mass index. Among men with HIV, after adjustment
for age, race and cardiovascular risk factors, EAT volume was
associated with the duration of combination ART. The duration
of use of reverse transcriptase inhibitor azidothymidine (AZT)
was associated with higher EAT volume than other ART. No
associations were demonstrated between duration of use of
either protease inhibitors, stavudine (d4T), or abacavir (ABC)
therapy, and EAT volume (12). Factors found to be independently
associated with raised EAT volume in PLHIV included age, male
sex, visceral adipose tissue, waist circumference, total cholesterol
and cumulative exposure to ART (13). Myocardial steatosis refers
to raised adipose tissue within the myocardium, which can be
measured using cardiac proton magnetic resonance spectroscopy
(MRS), a non-invasive means of quantifying myocardial lipids
by measuring their unique resonance frequency when passed
through a magnetic field (14). Magnetic resonance imaging
(MRI) and magnetic resonance spectroscopy (MRS) techniques
allow the determination of cardiac function, fibrosis, and fat
metabolism. Cardiac MRI allows determination of cardiac
function, using cine images, and fibrosis, using Gadolinium
contrast. Cardiac MRS is a technique that determines the
chemical composition of the heart and can determine, for
example, the fat content of the heart (Supplementary Figure 1).
These techniques were used in 129 participants and compared
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CARDIAC STEATOSIS, AS AN
INDEPENDENT RISK FACTOR FOR CVD
The question remains whether the relationship between
pericardial fat and cardiovascular disease is merely a marker
or mediator of risk. Recent data from the Multi-Ethnic Study
of Atherosclerosis, a prospective study with a median 12.2year follow-up of 4,234 participants found that in the general
population pericardial fat is associated with elevated rates of
CVD events, and increase left ventricular mass (20). There
is a clear relationship between pericardial fat and coronary
artherosclerosis. In PLHIV, The Multicentre AIDS Cohort
Study demonstrated that pericardial fat was associated with
coronary atherosclerosis. Among men with coronary artery
calcium (CAC) epicardial adipose tissue was associated with
the extent of CAC (p = 0.006) (12). Epicardial fat share the
same microcirculation as the myocardium, highlighting their
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FIGURE 1 | Assessment of myocardial steatosis using cardiac proton magnetic resonance spectroscopy (H1 MRS), a reliable, non-invasive means of quantifying
myocardial lipids. (A) Short-axis image of the left ventricle with a voxel (box) in the interventricular septum of the heart of a midventricular slice (inner box). (B)
Four-chamber image of the heart showing where the slice of the heart was selection. (C) An example of a proton MRS resonance spectrum, from a subject with HIV
with identified myocellular lipid peak used in quantifying myocardial lipid. Figure taken from Holloway et al. (7).

essential functional relationship (21). The Framingham Heart
Study found that pericardial fat but not intrathoracic fat was
associated with coronary artery calcification (22). The location
of fat deposits is therefore important in determining the
impact on the vasculature, further supporting the association
between pericardial steatosis and CVD (20). Recent studies have
highlighted the pro-inflammatory nature of pathological fat
deposits. Obese models have demonstrated a transformation of
perivascular adipose tissue into a pro-inflammatory phenotype
with the upregulation of proinflammatory cytokines (23). In
virologically suppressed PLHIV on ART, perivascular fat is
associated with biomarkers of inflammation, insulin resistance,
and subclinical atherosclerosis (24). The proximity of pericardial
fat combined with a pathological switch into a pro-inflammatory
state is believed to create an inflammatory milieu promoting
coronary artery disease in PLHIV.

Frontiers in Endocrinology | www.frontiersin.org

A cross-sectional analysis performed in obese subjects
identified that increasing myocardial triglyceride content
on MRS remained correlated to diastolic dysfunction after
controlling for LV mass, systolic blood pressure, and insulin
resistance (10). The term cardiac lipotoxicity refers to fatty-acid
sequestration and oxidation and is associated with a build-up
of toxic fatty-acid metabolites within cardiomyocytes, leading
to cardiomyopathy (25). Cardiac lipotoxicity may underline the
asymptomatic myocardial dysfunction seen in PLHIV. However
further studies are needed to investigate this association.
Increased rates of fatty acid oxidation found in obese models
impairs glucose oxidation (26). Impaired glucose metabolism
in cardiac steatosis is widely held as an important factor in
cardiac dysfunction. Cardiac-specific deletion of pyruvate
dehydrogenase, a rate limiting enzyme involved in glucose
oxygenation, results in impaired glucose oxidation rates and
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THERAPEUTICS TARGETS TO REDUCE
CVD RISK IN PLHIV

diastolic dysfunction (27). Cardiac lipotoxicity and impaired
glucose metabolism may explain cardiac dysfunction found in
PLHIV, which predominantly presents with diastolic dysfunction
(8). However further studies in PLHIV are needed to investigate
this association.
Weight loss, in obese subjects, has been shown to improve
impaired cardiac energetics and myocardial relaxation, thus
improving diastolic dysfunction (28). An improvement in cardiac
function associated with the reduction in cardiac steatosis would
support an aetiological link between cardiac steatosis and systolic
and diastolic dysfunction observed in PLHIV.

There is likely a complex interplay between untreated
inflammation and ongoing metabolic alterations leading to
fat deposition in PLHIV, likely translating to a difficulty
in finding a simple solution to reducing pericardial and
myocardial cardiac fat deposition. Given the higher proportion
of traditional modifiable risk factors in PLHIV, including;
smoking, hypertension, diabetes and dyslipidaemia, modification
of heart disease risk should start with these factors (40). Weight
loss in obese patients is associated with the reduction of cardiac
steatosis and improvement in cardiac function (28, 41), therefore,
aiming for a normal BMI is recommended. Medications aimed
at reducing cardiac steatosis is a potential therapeutic target for
the treatment of cardiac dysfunction in PLHIV.
Through decades of extensive research, heart disease in
patients with diabetes and obesity are understood as the result
of alterations in glucose and fat metabolism and inflammation,
leading to vascular dysfunction, structural, and metabolic heart
disease. We propose the same mechanisms may be implicated
in PLHIV and we can therefore learn from treatment used in
similar metabolic diseases to improve fat metabolism. Hence, the
next logical step would be to alter factors which lead to changes
in glucose and fat metabolism, which may alter pericardial
and myocardial fat deposition, in addition to reducing vascular
risk.
The emergence of newer diabetic medications, such as
glucagon-like peptide-1 (GLP-1) agonists and sodium/glucose
co-transporter (SGLT)2 inhibitors confer benefits on
cardiovascular outcomes in patients with diabetes (42, 43).
Perhaps these medications will confer such benefits in nondiabetic PLHIV in whom impaired glucose metabolism is
believed to be an important factor in the development of CVD.
Statins have become an important part of both primary and
secondary CVD prevention (44) In the SATURN trial, the use of
rosuvastatin and atorvastatin at their maximal dose in individuals
with angiographic evidence of CAD was associated significant
regression of coronary arthrosclerosis (45). Likewise, statins are
believed to have an important role in the prevention of CVD
events in PLHIV. However, the evidence for the use of statins
in PLHIV with otherwise low traditional risk factors for CVD
remains unclear. The SATURN-HIV study, a 96-week double
blind, randomized clinical trial, investigating the use rosuvastatin
in PLHIV on ART with raised inflammatory markers, found
significantly reduced low density lipid (LDL) levels and slower
progression of carotid artery intima-media thickening in the
treatment group (n = 72) compared to the placebo group (n
= 75). This study, however, did not demonstrate significant
change in coronary artery calcium (46). A randomized doubleblind placebo controlled trial where 40 PLHIV with subclinical
coronary atherosclerosis were randomized to 1 year of treatment
with atorvastatin (n = 19) or placebo (n = 21) found that
the treatment arm induced coronary plaque regression among
participants living with HIV (47). In addition to a reduction in
LDL levels, the use of rosuvastatin in PLHIV on ART is associated
with a reduction in markers of inflammation as well as T cell

INFLAMMATORY CHANGES CAUSING
STEATOSIS
Immunological derangements in both the innate and adaptive
immune system have been described in PLHIV. The Human
Immunodeficiency Virus primarily targets the adaptive immune
system resulting in CD4+ T cell depletion and CD8+ Tcell activation (29). The resulting derangement in the adaptive
immune system, marked by a high absolute CD8+ T-cell count
as well as a lower CD4: CD8 ratio, have been associated with
an increased risk of myocardial infarction among HIV-infected
individuals (30). In addition to T cell changes the phenotype
of macrophages is affected in PLHIV. Soluble CD14, a nonspecific marker of monocyte activation, a key cell in the innate
immune system and atherogenesis, has been associated with
calcified coronary plaque among PLHIV (31). The frequency of
patrolling non-classical monocytes CD14+CD16+ was elevated
among PLHIV presenting with an acute coronary syndrome and
also persisted among those with undetectable viral load (32).
These CD14+CD16+ monocytes subsets exhibit properties that
promote atherogenesis, including a higher affinity for vascular
surfaces and migration into atherosclerotic lesions (33). The
observed increased level of CD14+CD16+ monocytes subsets
may contribute to the elevated cardiovascular risk found in
PLHIV.
Despite viral suppression, PLHIV have evidence of
chronic systemic inflammation as demonstrated by elevated
inflammatory markers, which may underlie the increased risk
of ischaemic heart disease and cardiometabolic abnormalities
(34). Elevated C- reactive peptide (CRP), a non-specific acute
phase protein marker of inflammation, for instance, has been
associated with increased coronary events (35). A retrospective
analysis looking at PLHIV found that the presence of HIV and
an elevated CRP have a synergistic effect on acute myocardial
infarction (AMI) risk, with a hazard ratio of 4.11. Increased
CRP and HIV infection individually were each associated with
an approximately 2-fold increased risk for AMI compared to
those with neither risk factors (36). Non-HIV conditions with
systemic inflammation, such as systemic lupus erythematosus,
rheumatoid arthritis and diabetes mellitus, are associated with
increased pericardial fat and cardiac steatosis (37–39). Further
studies into the relationship of cardiac fat and inflammatory
conditions may show that inflammation is a shared pathway in
the development of pathologic heart fat.
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and monocyte activation (48). Therefore, the cardioprotective
action of statins in PLHIV is believed to occur at its effect
on metabolism and the immune system. As discussed above,
PLHIV are at a high risk of developing CVD with a cumulative
CVD incidence at the age of 60 of 20.5% compared to 12.8% in
the US general population (9). However, traditional CVD risk
scales under estimate CVD disease risk in PLHIV. Therefore, it
remains unclear if PLHIV with low CVD risk factors and 10year ACC/AHA risk of <7.5% would benefit from treatment.
The REPRIEVE trial, a randomized controlled trial assessing the
effectiveness of pitavastatin in reducing primary cardiovascular
events for patients on ART with 10-year ACC/AHA risk of
<7.5%, is expected to give light on the use of statins as primary
prevention for CVD in PLHIV with low CVD risk by the year
2020.
It is unknown whether reduced inflammation will lower
cardiac fat deposition. A recent randomized controlled trial using
the interleukin 1beta blocking agent, canakinumab, has been
shown to decrease myocardial infarction in people at risk (49). In
support of its use in PLHIV, Huse et al. demonstrated a reduction
in inflammatory markers (IL-6, hsCRP) in 10 subjects with
HIV treated with canakinumab (50). The use of canakinumab,
however, was associated with higher incidence of fatal infection
than the placebo group which may limit its use in PLHIV (49).
The use of rosuvastatin in ART treated PLHIV was associated
with a reduction in markers of inflammation as well as T
cell and monocyte activation. There are several ongoing trials
evaluating the effects of therapeutics including methotrexate,
canakinumab, and probiotics for vasculature function and/or
vascular inflammation, which could potentially translate to
improve cardiac fat metabolism.

chronic metabolic and inflammatory changes, from both
the virus and cART. Despite viral suppression, PLHIV have
evidence of chronic systemic inflammation. Most, if not all
systemic inflammatory diseases, increase the risk of abnormal
fat metabolism, myocardial infarction and heart failure,
emphasizing the role of inflammation in the pathogenesis of
heart disease. Therefore, the way to improve cardiac outcomes
in PLHIV may be dependent on improving inflammatory
and metabolic states. Cardiac steatosis in HIV is not simply
age-related change and as such, a systemic approach to
understanding fat deposition is required to improve HIV
outcomes.

CONCLUSION

SUPPLEMENTARY MATERIAL

The era of cART has been associated with a paradigm shift
from cardiomyopathy to cardiometabolic and atherosclerotic
disease in PLHIV; which are both likely sequelae of untreated

The Supplementary Material for this article can be found
online at: https://www.frontiersin.org/articles/10.3389/fendo.
2018.00529/full#supplementary-material

AUTHOR CONTRIBUTIONS
MJ performed a literature review of the current evidence
regarding cardiac steatosis within people living with HIV. MJ
was involved in the planning and drafting of the article. CH was
involved in the conception of the article. CH provided guidance
as to relevant latest contributions in the field of cardiac steatosis.
CH drafted the section on therapeutic targets as well as critical
revision the article.

FUNDING
CH has received honoraria from Bayer, ViiV and Gilead.

ACKNOWLEDGMENTS
We would like to acknowledge Dr. Alex Sheiban for
proofreading the article.

REFERENCES

6. Freiberg MS, Chang CC, Kuller LH, Skanderson M, Lowy E, Kraemer KL. HIV
infection and the risk of acute myocardial infarction. JAMA Internal Medicine
(2013) 173:614–22. doi: 10.1001/jamainternmed.2013.3728
7. Holloway CJ, Ntusi N, Suttie J, Mahmod M, Wainwright E, Clutton G, et
al. Comprehensive cardiac magnetic resonance imaging and spectroscopy
reveal a high burden of myocardial disease in HIV patients. Circulation (2013)
128:814–22. doi: 10.1161/CIRCULATIONAHA.113.001719
8. Freiberg MS, Chang C-CH, Skanderson M, Patterson OV, DuVall SL,
Brandt CA, et al. Association between HIV infection and the risk
of heart failure with reduced ejection fraction and preserved ejection
fraction in the antiretroviral therapy era. JAMA Cardiol. (2017) 2:536–46.
doi: 10.1001/jamacardio.2017.0264
9. Losina E, Hyle EP, Borre ED, Linas BP, Sax PE, Weinstein MC, et al. (2017).
Projecting 10-year, 20-year, and lifetime risks of cardiovascular disease in
persons living with human immunodeficiency virus in the United States. Clin.
Infect. Dis. 65, 1266–1271. doi: 10.1093/cid/cix547
10. Banerjee R, Rial B, Holloway CJ, Lewandowski AJ, Robson MD, Osuchukwu
C, et al. Evidence of a direct effect of myocardial steatosis on LV hypertrophy
and diastolic dysfunction in adult and adolescent obesity. JACC Cardiovasc.
Imag. (2015) 8:1468–70. doi: 10.1016/j.jcmg.2014.12.019

1. Trickey A, May MT, Vehreschild J, Obel N, Gill MJ, Crane H, et al.
Cause-specific mortality in HIV-positive patients who survived ten
years after starting antiretroviral therapy. PLOS ONE 11:e0160460.
doi: 10.1371/journal.pone.0160460
2. Feinstein MJ, Bahiru E, Achenbach C, Longenecker CT, Hsue P, SoArmah K, et al. Patterns of cardiovascular mortality for HIV-infected adults
in the United States: 1999 to 2013. Am J Cardiol. (2016) 117:214–20.
doi: 10.1016/j.amjcard.2015.10.030
3. Heidenreich PA, Eisenberg MJ, Kee LL, Somelofski CA, Hollander H, Schiller
NB, et al. Pericardial effusion in AIDS. Incidence and survival. Circulation
(1995) 92:3229–34.
4. Remick J, Georgiopoulou V, Marti C, Ofotokun I, Kalogeropoulos A, Lewis W,
et al. Heart failure in patients with human immunodeficiency virus infection:
epidemiology, pathophysiology, treatment, and future research. Circulation
(2014) 129:1781–9. doi: 10.1161/CIRCULATIONAHA.113.004574
5. Bloomfield GS, Alenezi F, Barasa FA, Lumsden R, Mayosi BM, Velazquez EJ.
Human immunodeficiency virus and heart failure in low- and middle-income
countries. JACC Heart Failure (2015) 3:579–90. doi: 10.1016/j.jchf.2015.05.003

Frontiers in Endocrinology | www.frontiersin.org

5

October 2018 | Volume 9 | Article 529

Jacob and Holloway

Is HIV Associated With an “Obese Heart”?

28. Rider OJ, Francis JM, Tyler D, Byrne J, Clarke K, Neubauer S. Effects of
weight loss on myocardial energetics and diastolic function in obesity. Int J
Cardiovasc Imag. (2013) 29:1043–50. doi: 10.1007/s10554-012-0174-6
29. Sodora
DL,
Silvestri
G.
Immune
activation
and
AIDS
pathogenesis. AIDS (2008) 22:439–46. doi: 10.1097/QAD.0b013e3282
f2dbe7
30. Lang S, Mary-Krause M, Simon A, Partisani M, Gilquin J, Cotte L, et al.
HIV replication and immune status are independent predictors of the risk
of myocardial infarction in HIV-infected individuals. Clin Infect Dis. (2012)
55:600–7. doi: 10.1093/cid/cis489
31. Longenecker CT, Jiang Y, Orringer CE, Gilkeson RC, Debanne S,
Funderburg NT, et al. Soluble CD14 is independently associated with
coronary calcification and extent of subclinical vascular disease in treated
HIV infection. AIDS (2014) 28:969–77. doi: 10.1097/QAD.00000000000
00158
32. Funderburg NT, Zidar DA, Shive C, Lioi A, Mudd J, Musselwhite LW,
et al. Shared monocyte subset phenotypes in HIV-1 infection and in
uninfected subjects with acute coronary syndrome. Blood (2012) 120:4599–
608. doi: 10.1182/blood-2012-05-433946
33. Ziegler-Heitbrock L. The CD14+ CD16+ blood monocytes: their role
in infection and inflammation. J Leukocyte Biol. (2007) 81:584–92.
doi: 10.1189/jlb.0806510
34. Noursadeghi M, Miller RF. Clinical value of C-reactive protein
measurements in HIV-positive patients. Int J STD AIDS (2005) 16:438–41.
doi: 10.1258/0956462054094006
35. Ridker PM. High-sensitivity C-reactive protein, inflammation, and
cardiovascular risk: from concept to clinical practice to clinical benefit.
Am Heart J. (2004) 148:19–26. doi: 10.1016/j.ahj.2004.04.028
36. Triant VA, Meigs JB, Grinspoon SK. Association of C-reactive protein
and HIV infection with acute myocardial infarction. J Acquired Immune
Deficiency Syndromes (2009) 51:268–73. doi: 10.1097/QAI.0b013e318
1a9992c
37. McGavock JM, Lingvay I, Zib I, Tillery T, Salas N, Unger R,
et al. Cardiac steatosis in diabetes mellitus: a 1H-magnetic
resonance spectroscopy study. Circulation (2007) 116:1170–5.
doi: 10.1161/CIRCULATIONAHA.106.645614
38. Lipson A, Alexopoulos N, Hartlage GR, Arepalli C, Oeser A, Bian
A, et al. Epicardial adipose tissue is increased in patients with
systemic lupus erythematosus. Arthrosclerosis (2012) 223:389–93.
doi: 10.1016/j.atherosclerosis.2012.06.006
39. Fatma E, Bunyamin K, Savas S, Mehmet U, Selma Y, Ismail B, et al. Epicardial
fat thickness in patients with rheumatoid arthritis. African Health Sci. (2015)
15:489–95. doi: 10.4314/ahs.v15i2.23
40. Zoest RA, van der Valk M, Wit FW, Vaartjes I, Kooij KW, Hovius
JW, et al. Suboptimal primary and secondary cardiovascular disease
prevention in HIV-positive individuals on antiretroviral therapy. Eur
J Preventive Cardiol. (2017) 24:1297–307. doi: 10.1177/20474873177
14350
41. Utz W, Engeli S, Haufe S, Kast P, Böhnke J, Haas V, et al. Moderate dietary
weight loss reduces myocardial steatosis in obese and overweight women. Int
J Cardiol. (2013) 167:905–9. doi: 10.1016/j.ijcard.2012.03.104
42. Persson F, Nyström T, Jørgensen ME, Carstensen B, Gulseth
HL, Thuresson M, et al. Dapagliflozin is associated with lower
risk of cardiovascular events and all-cause mortality in people
with type 2 diabetes (CVD-REAL Nordic) when compared with
dipeptidyl peptidase-4 inhibitor therapy: a multinational observational
study. Diabetes Obes Metab. (2017). 20:344–51. doi: 10.1111/dom.
13077
43. Toulis KA, Hanif W, Saravanan P, Willis BH, Marshall T, Kumarendran
B, et al. All-cause mortality in patients with diabetes under
glucagon-like peptide-1 agonists: a population-based, open cohort
study. Diab Metab. (2017) 43:211–6. doi: 10.1016/j.diabet.2017.
02.003
44. Cholesterol Treatment Trialists Collaborators. Cholesterol Treatment
Trialists’ (CTT). The effects of lowering LDL cholesterol with statin
therapy in people at low risk of vascular disease: meta-analysis of
individual data from 27 randomised trials. Lancet (2012) 380:581–90.
doi: 10.1016/S0140-6736(12)60367-5

11. Granér M, Siren R, Nyman K, Lundbom J, Hakkarainen A, Pentikäinen MO,
et al. Cardiac steatosis associates with visceral obesity in nondiabetic obese
men. J Clin Endocrinol Metab. (2013) 98:1189–97. doi: 10.1210/jc.2012-3190
12. Brener M, Ketlogetswe K, Budoff M, Jacobson LP, Li X, Rezaeian P, et
al. Epicardial fat is associated with duration of antiretroviral therapy and
coronary atherosclerosis: the multicenter AIDS cohort study. AIDS (2014)
28:1635–44. doi: 10.1097/QAD.0000000000000116
13. Guaraldi G, Scaglioni R, Zona S, Orlando G, Carli F, Ligabue
G, et al. Epicardial adipose tissue is an independent marker of
cardiovascular risk in HIV-infected patients. AIDS (2011) 25:1199–205.
doi: 10.1097/QAD.0b013e3283474b9f
14. Rial B, Robson MD, Neubauer S, and Schneider JE. Rapid quantification
of myocardial lipid content in humans using single breath-hold 1H
MRS at 3 Tesla. Magn. Res. Med. (2011) 66:619–24 doi: 10.1002/
mrm.23011
15. Cade WT, Reeds DN, Overton ET, Herrero P, Waggoner AD, DavilaRoman VG, et al. Effects of human immunodeficiency virus and metabolic
complications on myocardial nutrient metabolism, blood flow, and oxygen
consumption: a cross-sectional analysis. Cadiovasc Diabetol. (2011) 10:111.
doi: 10.1186/1475-2840-10-111
16. Brener MI, Post WS, Haberlen SA, Zhang L, Palella FJ Jr, Jacobson
LP, et al. Comparison of insulin resistance to coronary atherosclerosis
in human immunodeficiency virus infected and uninfected men (from
the multicenter AIDS cohort study). Am J Cardiol. (2016) 117:992–1000.
doi: 10.1016/j.amjcard.2015.12.037
17. Miller KD, Jones E, Yanovski JA, Shankar R, Feuerstein I, Falloon J. Visceral
abdominal-fat accumulation associated with use of indinavir. Lancet (1998)
21:871–5.
18. Quercia R, Roberts J, Martin-Carpenter L, Zala C. Comparative changes
of lipid levels in treatment-naive, HIV-1-infected adults treated with
dolutegravir vs. efavirenz, raltegravir, and ritonavir-boosted darunavirbased regimens over 48 weeks. Clin Drug Investig. (2015) 35:211–9.
doi: 10.1007/s40261-014-0266-2
19. McComsey GA, Moser C, Currier J, Ribaudo HJ, Paczuski P, Dub,é MP,
et al. Body composition changes after initiation of raltegravir or protease
inhibitors: ACTG A5260s. Clin Infect. Dis. (2016) 62:853–62. doi: 10.1093/cid/
ciw017
20. Shah RV, Anderson A, Ding J, Budoff M, Rider O, Petersen SE, et al.
Pericardial, but not hepatic, Fat by CT is associated with CV outcomes and
structure: the multi-ethnic study of atherosclerosis. JACC Cardiovasc Imag.
(2017) 10:1016–27. doi: 10.1016/j.jcmg.2016.10.024
21. Iacobellis G, Corradi D, Sharma AM. Epicardial adipose tissue: anatomic,
biomolecular and clinical relationships with the heart. Nat Clin Pract
Cardiovasc Med. (2005) 2:536–43. doi: 10.1038/ncpcardio0319
22. Rosito GA, Massaro JM, Hoffmann U, Ruberg FL, Mahabadi AA, Vasan
RS, et al. (2008). Pericardial fat, visceral abdominal fat, cardiovascular
disease risk factors, and vascular calcification in a communitybased sample: the Framingham Heart Study. Circulation 117:605–13.
doi: 10.1161/CIRCULATIONAHA.107.743062
23. Omar A, Chatterjee TK, Tang Y, Hui DY, Weintraub NL.
Proinflammatory phenotype of perivascular adipocytes. Arteriosclerosis
Thrombosis Vasc Biol. (2014) 34:1631–6. doi: 10.1161/ATVBAHA.114.3
03030
24. Longenecker CT, Jiang Y, Yun CH, Debanne S, Funderburg NT, Lederman
MM, et al. Perivascular fat, inflammation, and cardiovascular risk in HIVinfected patients on antiretroviral therapy. Int J Cardiol. (2013) 168:4039–45.
doi: 10.1016/j.ijcard.2013.06.059
25. D’Souza K, Nzirorera C, Kienesberger PC. Lipid metabolism and signaling
in cardiac lipotoxicity. Biochim Biophys Acta (2016) 1861:1555–68.
doi: 10.1016/j.bbalip.2016.02.016
26. Wang P, Lloyd SG, Zeng H, Bonen A, Chatham JC. Impact of altered
substrate utilization on cardiac function in isolated hearts from Zucker
diabetic fatty rats. Am J Physiol Heart Circul Physiol. (2005) 228:H2102–10.
doi: 10.1152/ajpheart.00935.2004
27. Gopal K, Almutairi M, Al Batran R, Eaton F, Gandhi M, Ussher JR. Cardiacspecific deletion of pyruvate dehydrogenase impairs glucose oxidation rates
and induces diastolic dysfunction. Front Cardiovasc Med. (2018) 6:17.
doi: 10.3389/fcvm.2018.00017

Frontiers in Endocrinology | www.frontiersin.org

6

October 2018 | Volume 9 | Article 529

Jacob and Holloway

Is HIV Associated With an “Obese Heart”?

50. Hsue P, Deeks SG, Ishai AE, Hur S, Li D, Sterman F, et al. IL-1β inhibition
significantly reduces atherosclerotic inflammation in treated HIV. In: 2017
Conference on Retroviruses and Opportunistic Infections (CROI 2017) 13–16
February. Seattle, WA (2017).

45. Nicholls SJ, Ballantyne CM, Barter PJ, Chapman MJ, Erbel RM, Libby P, et al.
Effect of two intensive statin regimens on progression of coronary disease. N
Engl J Med. (2011) 365:2078–87. doi: 10.1056/NEJMoa1110874
46. Longenecker CT, Sattar A, Gilkeson R, McComsey GA. Rosuvastatin
slows progression of subclinical atherosclerosis in patients with treated
HIV infection. AIDS (2016) 30:195–203. doi: 10.1097/QAD.00000000000
01167
47. Lo J, Lu MT, Ihenachor EJ, Wei J, Looby SE, Fitch KV, et al. Effects
of statin therapy on coronary artery plaque volume and highrisk plaque morphology in HIV-infected patients with subclinical
atherosclerosis:
a
randomised,
double-blind,
placebo-controlled
trial. Lancet HIV (2015) 2:e52–63. doi: 10.1016/S2352-3018(14)
00032-0
48. Funderburg NT, Jiang Y, Debanne SM, Labbato D, Juchnowski S,
Ferrari B, et al. Rosuvastatin reduces vascular inflammation and Tcell and monocyte activation in HIV-infected subjects on antiretroviral
therapy. J Acquired Immune Deficiency Syndromes (2015) 68:396–404.
doi: 10.1097/QAI.0000000000000478
49. Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C,
et al. Antiinflammatory therapy with canakinumab for atherosclerotic
disease. N Engl J Med. (2017) 377:1119–31. doi: 10.1056/NEJMoa
1707914

Frontiers in Endocrinology | www.frontiersin.org

Conflict of Interest Statement: CH has received unrestricted research funding
from Bayer, travel grants from Gilead Sciences and honoraria from Bayer, ViiV,
and Gilead.
The remaining author declares that the research was conducted in the absence of
any commercial or financial relationships that could be construed as a potential
conflict of interest.
The handling Editor declared a shared affiliation, though no other collaboration,
with one of the authors CH.
Copyright © 2018 Jacob and Holloway. This is an open-access article distributed
under the terms of the Creative Commons Attribution License (CC BY). The use,
distribution or reproduction in other forums is permitted, provided the original
author(s) and the copyright owner(s) are credited and that the original publication
in this journal is cited, in accordance with accepted academic practice. No use,
distribution or reproduction is permitted which does not comply with these terms.

7

October 2018 | Volume 9 | Article 529

